Literature DB >> 6653610

97Ru-transferrin uptake in tumor and abscess.

P Som, Z H Oster, K Matsui, G Guglielmi, B R Persson, M L Pellettieri, S C Srivastava, P Richards, H L Atkins, A B Brill.   

Abstract

The uptake of 97Ru-transferrin (Ru-TF) in tumor and abscess bearing animals was compared with 67Ga-citrate (Ga), 123I-transferrin (I-TF), and several other plasma proteins. Maximal concentration in tumor of Ru-TF in mice was three times higher than 67Ga-citrate (16.80 +/- 4.20 vs 5.08 +/- 0.58% D/g) although it occurred later (24 h compared with 67Ga which reached its maximum 2 h after injection). Whole body autoradiography (WBARG) with 103Ru-transferrin (103Ru-TF) in tumor and abscess bearing rats demonstrated details of the distribution within these lesions. Turpentine-induced abscesses in the rabbits could be visualized with the gamma camera as early as 30 min post-injection of Ru-TF. It seems, therefore, that Ru-TF can be used for tumor and abscess localization. The results indicate that Ru-TF may have some advantages over 67Ga-citrate because of the higher concentration in the lesions. 123I-transferrin reached a concentration in tumor similar to 67Ga (6.89 +/- 1.67 vs 5.08 +/- 0.58% D/g) but had a very low tumor to blood ratio (0.64). The three compounds investigated (Ru-TF, I-TF and ionic Ga, which binds instantaneously to TF in vivo) have a common ligand, transferrin. It appears, therefore, that tumor affinity is a property of the radionuclide-ligand complex rather than of the radionuclide itself.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6653610     DOI: 10.1007/BF00598908

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  4 in total

1.  Transferrin receptors and gallium-67 uptake in vitro.

Authors:  D C Chen; B Newman; R M Turkall; M F Tsan
Journal:  Eur J Nucl Med       Date:  1982

2.  97Ru-DMSA for delayed renal imaging.

Authors:  Z H Oster; P Som; M C Gil; A G Goldman; R G Fairchild; G E Meinken; S C Srivastava; H L Atkins; P Richards; A B Brill
Journal:  Radiology       Date:  1981-10       Impact factor: 11.105

3.  Ruthenium-97 hepatobiliary agents for delayed studies of the biliary tract. I. ru-97 PIPIDA: concise communication.

Authors:  E R Schachner; M C Gil; H L Atkins; P Som; S C Srivastava; J Badia; D F Sacker; R G Fairchild; P Richards
Journal:  J Nucl Med       Date:  1981-04       Impact factor: 10.057

4.  Ruthenium-97 DTPA: a new radiopharmaceutical for cisternography.

Authors:  Z H Oster; P Som; M C Gil; R G Fairchild; A G Goldman; E R Schachner; D F Sacker; H L Atkins; G E Meinken; S C Srivastava; P Richards; A B Brill
Journal:  J Nucl Med       Date:  1981-03       Impact factor: 10.057

  4 in total
  6 in total

1.  Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.

Authors:  Brian M Zeglis; Jacob L Houghton; Michael J Evans; Nerissa Viola-Villegas; Jason S Lewis
Journal:  Inorg Chem       Date:  2013-12-06       Impact factor: 5.165

2.  Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MS.

Authors:  Michael Groessl; Mattia Terenghi; Angela Casini; Lisa Elviri; Ryszard Lobinski; Paul J Dyson
Journal:  J Anal At Spectrom       Date:  2010-03       Impact factor: 4.023

3.  Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse.

Authors:  R Gagliardi; G Sava; S Pacor; G Mestroni; E Alessio
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

4.  Ruthenium ammine complexes as electron acceptors for growth stimulation by plasma membrane electron transport.

Authors:  J F Laliberté; I L Sun; F L Crane; M J Clarke
Journal:  J Bioenerg Biomembr       Date:  1987-02       Impact factor: 2.945

Review 5.  Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.

Authors:  Michael J Evans
Journal:  Cancer Discov       Date:  2012-10-05       Impact factor: 39.397

6.  Annotating MYC status with 89Zr-transferrin imaging.

Authors:  Jason P Holland; Michael J Evans; Samuel L Rice; John Wongvipat; Charles L Sawyers; Jason S Lewis
Journal:  Nat Med       Date:  2012-09-23       Impact factor: 53.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.